{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:54:22Z","timestamp":1791665662305,"version":"4.3.4"},"reference-count":40,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Vascular resection and reconstruction during pancreatoduodenectomy (PD) have evolved from rare and controversial procedures into essential components of surgical management for selected patients with locally advanced pancreatic ductal adenocarcinoma (PDAC). Venous resection is now widely accepted and routinely performed in high-volume centers, whereas arterial resection and artery-sparing divestment remain selectively applied because of their technical demands and concerns regarding perioperative risk and oncologic benefit. Accumulating contemporary evidence indicates that venous resection can be performed with acceptable safety, with 30-day mortality rates generally ranging from 3% to 5% and median overall survival of approximately 18\u201326 months when margin-negative (R0) resection is achieved. Arterial resections, most commonly involving the common hepatic, celiac, or superior mesenteric arteries, have been increasingly utilized in highly selected patients, particularly following neoadjuvant therapy, achieving R0 resection rates of approximately 65\u201375% and median overall survival of 20\u201328 months. Arterial divestment has emerged as a promising artery-sparing strategy, offering comparable oncologic outcomes with reduced surgical morbidity in appropriately selected cases. Collectively, these advances have expanded the boundaries of resectability in PDAC, enabling surgical intervention in patients previously deemed inoperable. Venous resection is now considered an oncologically sound extension of standard PD, whereas arterial resection and divestment should remain restricted to carefully selected patients demonstrating favorable biologic behavior and response to neoadjuvant therapy. Future progress in this field will likely depend on improved biologic stratification, enhanced intraoperative perfusion assessment, and the integration of hybrid open and endovascular techniques.<\/jats:p>","DOI":"10.3390\/cancers18040577","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T09:16:08Z","timestamp":1770801368000},"page":"577","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Vascular Resection, Reconstruction, and Divestment in Pancreatoduodenectomy: Expanding Boundaries in Pancreatic Cancer Surgery"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5276-0699","authenticated-orcid":false,"given":"Dimitrios","family":"Moris","sequence":"first","affiliation":[{"name":"Department of Surgery, MedStar Georgetown Transplant Institute, Medstar Georgetown University Hospital, Washington, DC 20007, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Surgery, MedStar Georgetown Transplant Institute, Medstar Georgetown University Hospital, Washington, DC 20007, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kroemer","sequence":"additional","affiliation":[{"name":"Department of Surgery, MedStar Georgetown Transplant Institute, Medstar Georgetown University Hospital, Washington, DC 20007, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0408-4817","authenticated-orcid":false,"given":"Benjamin","family":"Weinberg","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R.","family":"Unger","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA"},{"name":"Radiation Oncology, MedStar Georgetown University Hospital, Washington, DC 20007, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim G.","family":"Haddad","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Medstar Georgetown University Hospital, Washington, DC 20007, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Fishbein","sequence":"additional","affiliation":[{"name":"Department of Surgery, MedStar Georgetown Transplant Institute, Medstar Georgetown University Hospital, Washington, DC 20007, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9552-3995","authenticated-orcid":false,"given":"Yuri S.","family":"Genyk","sequence":"additional","affiliation":[{"name":"Department of Surgery, MedStar Georgetown Transplant Institute, Medstar Georgetown University Hospital, Washington, DC 20007, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"ref_1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.gassur.2004.09.046","article-title":"Pancreaticoduodenectomy with vascular resection: Margin status and survival duration","volume":"8","author":"Tseng","year":"2004","journal-title":"J. Gastrointest. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.hpb.2017.02.438","article-title":"Splenic vein reconstruction is unnecessary in pancreatoduodenectomy combined with resection of the superior mesenteric vein-portal vein confluence according to short-term outcomes","volume":"19","author":"Tanaka","year":"2017","journal-title":"HPB"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/SLA.0b013e31823ac299","article-title":"Arterial resection during pancreatectomy for pancreatic cancer: A systematic review and meta-analysis","volume":"254","author":"Mollberg","year":"2011","journal-title":"Ann. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.hpb.2018.07.017","article-title":"Pancreatectomy with arterial resection is superior to palliation in patients with borderline resectable or locally advanced pancreatic cancer","volume":"21","author":"Rangelova","year":"2019","journal-title":"HPB"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/SLA.0000000000001850","article-title":"Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients","volume":"264","author":"Hackert","year":"2016","journal-title":"Ann. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.1245\/s10434-025-17751-6","article-title":"Periarterial Divestment of the Superior Mesenteric Artery Utilizing Dual Artery First Approach for Locally Advanced Pancreatic Cancer","volume":"32","author":"Nguyen","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF02469723","article-title":"Regional pancreatectomy for cancer of the pancreas, ampulla and other related sites","volume":"13","author":"Fortner","year":"1983","journal-title":"Jpn. J. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.surg.2014.02.001","article-title":"Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)","volume":"155","author":"Bockhorn","year":"2014","journal-title":"Surgery"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.hpb.2020.11.008","article-title":"Graft type for superior mesenteric and portal vein reconstruction in pancreatic surgery\u2014A systematic review","volume":"23","author":"Labori","year":"2021","journal-title":"HPB"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e1890","DOI":"10.1590\/0102-67202025000021e1890","article-title":"Pancreatoduodenectomy with vascular reconstruction versus chemotherapy alone in patients with locally advanced pancreatic cancer: A systematic review","volume":"38","author":"Costa","year":"2025","journal-title":"Arq. Bras. De Cir. Dig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/archsurg.138.12.1316","article-title":"Extended lymphadenectomy and vein resection for pancreatic head cancer: Outcomes and implications for therapy","volume":"138","author":"Capussotti","year":"2003","journal-title":"Arch. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/SLA.0b013e318263da2f","article-title":"Pancreatic ductal adenocarcinoma: Is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a \u201ctrue\u201d R0 resection?","volume":"257","author":"Konstantinidis","year":"2013","journal-title":"Ann. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/SLA.0000000000002557","article-title":"The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma","volume":"269","author":"Ghaneh","year":"2019","journal-title":"Ann. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Peng, C., Zhou, D., Meng, L., Cao, Y., Zhang, H., Pan, Z., and Lin, C. (2019). The value of combined vein resection in pancreaticoduodenectomy for pancreatic head carcinoma: A meta-analysis. BMC Surg., 19.","DOI":"10.1186\/s12893-019-0540-6"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1007\/s00268-012-1461-z","article-title":"Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: A meta-analysis","volume":"36","author":"Zhou","year":"2012","journal-title":"World J. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.hpb.2016.11.013","article-title":"Pancreatoduodenectomy with venous or arterial resection: A NSQIP propensity score analysis","volume":"19","author":"Beane","year":"2017","journal-title":"HPB"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/bjs.6483","article-title":"Interposition graft with polytetrafluoroethylene for mesenteric and portal vein reconstruction after pancreaticoduodenectomy","volume":"96","author":"Stauffer","year":"2009","journal-title":"Br. J. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Noel, C., Azeez, A., Du Preez, A., and Noel, K. (2025). Arterial Resections in Pancreatic Cancer-An Updated Systematic Review and Meta-Analysis. Cancers, 17.","DOI":"10.3390\/cancers17091540"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.14701\/ahbps.24-118","article-title":"Survival after vascular resections in patients with borderline resectable or locally advanced pancreatic head cancer: A systematic review","volume":"28","author":"Papakonstantinou","year":"2024","journal-title":"Ann. Hepato-Biliary-Pancreat. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11605-017-3556-1","article-title":"Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy","volume":"22","author":"Kluger","year":"2018","journal-title":"J. Gastrointest. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Virtanen, J., Aro, E., Lehtimaki, T.E., Vuorela, T., Kokkola, A., Haglund, C., Vikatmaa, P., and Seppanen, H. (2025). Short Term Safety and Long Term Patency of Arterial Reconstruction in Pancreatic Surgery. Eur. J. Vasc. Endovasc. Surg.","DOI":"10.1016\/j.ejvs.2025.09.021"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/SLA.0000000000006350","article-title":"Outcomes of Visceral Arterial Interposition Graft Reconstruction for Locally Advanced Pancreatic Cancer","volume":"281","author":"Yonkus","year":"2025","journal-title":"Ann. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/SLA.0000000000004054","article-title":"Arterial Resection in Pancreatic Cancer Surgery: Effective After a Learning Curve","volume":"275","author":"Loos","year":"2022","journal-title":"Ann. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ishida, H., Franklin, O., Franco, S.R., Clark, T.J., Stoop, T.F., Kirsch, M.J., Schulick, R.D., and Del Chiaro, M. (2025). Surgery for Borderline Resectable and Locally Advanced Pancreatic Cancer with Arterial Encasement after Neoadjuvant Therapy: A Single-center Experience. Ann. Surg.","DOI":"10.1097\/SLA.0000000000006690"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Inoue, Y., Oba, A., Ono, Y., Sato, T., Ito, H., and Takahashi, Y. (2021). Radical Resection for Locally Advanced Pancreatic Cancers in the Era of New Neoadjuvant Therapy-Arterial Resection, Arterial Divestment and Total Pancreatectomy. Cancers, 13.","DOI":"10.3390\/cancers13081818"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: A systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1245\/s10434-021-10276-8","article-title":"Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis","volume":"28","author":"Janssen","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1245\/s10434-021-11202-8","article-title":"Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity","volume":"29","author":"Hill","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Burkon, P., Trna, J., Slavik, M., Nemecek, R., Kazda, T., Pospisil, P., Dastych, M., Eid, M., Novotny, I., and Prochazka, T. (2022). Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer-A Critical Review and Practical Consideration. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102480"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.21037\/jgo.2016.03.15","article-title":"Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer","volume":"7","author":"Mellon","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.3748\/wjg.v19.i16.2569","article-title":"Portal vein stenosis after pancreatectomy following neoadjuvant chemoradiation therapy for pancreatic cancer","volume":"19","author":"Tsuruga","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/0284186X.2016.1256497","article-title":"Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy","volume":"56","author":"Mellon","year":"2017","journal-title":"Acta Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Nelson, B., Barrord, M., Wang, K., Wages, N.A., Sudhoff, M., and Kharofa, J. (2022). Relationship of dose to vascular target volumes and local failure in pancreatic cancer patients undergoing neoadjuvant chemoradiation. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.906484"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13014-020-01511-9","article-title":"The role of intraoperative radiation therapy in resectable pancreatic cancer: A systematic review and meta-analysis","volume":"15","author":"Jin","year":"2020","journal-title":"Radiat. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13014-016-0753-0","article-title":"Intraoperative radiation therapy (IORT) in pancreatic cancer","volume":"12","author":"Krempien","year":"2017","journal-title":"Radiat. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3349\/ymj.2022.63.5.405","article-title":"Intraoperative Radiotherapy for Resectable Pancreatic Cancer Using a Low-Energy X-Ray Source: Postoperative Complications and Early Outcomes","volume":"63","author":"Cho","year":"2022","journal-title":"Yonsei Med. J."},{"key":"ref_40","first-page":"91","article-title":"ESTRO IORT Task Force\/ACROP recommendations for intraoperative radiation therapy in borderline-resected pancreatic cancer","volume":"23","author":"Calvo","year":"2020","journal-title":"Clin. Transl. Radiat. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/577\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T09:36:29Z","timestamp":1770802589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cancers18040577"],"URL":"https:\/\/doi.org\/10.3390\/cancers18040577","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]}}}